Rapidly progressive DM-/CADM-ILD with the anti-MDA5 antibody is the most intractable condition and requires immediate combined immunosuppressive therapy with GCs, CNIs, and IVCY. Here, IFIH1 is linked to clinically amyopathic dermatomyositis.